AIM: To determine the phenotypic effects of belinostat (bel) and bortezomib (bor) against pancreatic cancer (PC) and hepatocellular cancer (HCC) cell lines. MATERIALS AND METHODS: Antiproliferative effects were assessed using a sulforhodamine B assay. Synergy was evaluated using the Chou and Talalay method. Apoptosis was measured by caspase-3/-7 activity and PARP cleavage. Downstream effector proteins were detected via immunoblotting. Quantitative nuclear magnetic resonance (NMR)-based metabolomics analysis was performed. RESULTS: There were single-agent antiproliferative effects against PC and HCC cell lines; the combination of bel and bor (bel+bor) had a synergistic effect. There was up to a 45-fold induction of apoptosis over the control. Post-treatment cell death was associated with p21 up-regulation, more pronounced with treatment with bel+bor. Treatment with bel+bor enhanced hyperacetylation of histone H3 over single-agent bel. A metabolic signature was established for treatments with bor and bel+bor. CONCLUSION: The combination of bel+bor displayed significant antiproliferative activity against PC and HCC cell lines, with exhibiting synergistic antiproliferative and proapoptotic patterns even at suboptimal single-agent doses.
AIM: To determine the phenotypic effects of belinostat (bel) and bortezomib (bor) against pancreatic cancer (PC) and hepatocellular cancer (HCC) cell lines. MATERIALS AND METHODS: Antiproliferative effects were assessed using a sulforhodamine B assay. Synergy was evaluated using the Chou and Talalay method. Apoptosis was measured by caspase-3/-7 activity and PARP cleavage. Downstream effector proteins were detected via immunoblotting. Quantitative nuclear magnetic resonance (NMR)-based metabolomics analysis was performed. RESULTS: There were single-agent antiproliferative effects against PC and HCC cell lines; the combination of bel and bor (bel+bor) had a synergistic effect. There was up to a 45-fold induction of apoptosis over the control. Post-treatment cell death was associated with p21 up-regulation, more pronounced with treatment with bel+bor. Treatment with bel+bor enhanced hyperacetylation of histone H3 over single-agent bel. A metabolic signature was established for treatments with bor and bel+bor. CONCLUSION: The combination of bel+bor displayed significant antiproliferative activity against PC and HCC cell lines, with exhibiting synergistic antiproliferative and proapoptotic patterns even at suboptimal single-agent doses.
Authors: Douglas J Kominsky; Jelena Klawitter; Jaimi L Brown; Laszlo G Boros; Junia V Melo; S Gail Eckhardt; Natalie J Serkova Journal: Clin Cancer Res Date: 2009-04-28 Impact factor: 12.531
Authors: J Borrow; V P Stanton; J M Andresen; R Becher; F G Behm; R S Chaganti; C I Civin; C Disteche; I Dubé; A M Frischauf; D Horsman; F Mitelman; S Volinia; A E Watmore; D E Housman Journal: Nat Genet Date: 1996-09 Impact factor: 38.330
Authors: Jane A Plumb; Paul W Finn; Robert J Williams; Morwenna J Bandara; M Rosario Romero; Claire J Watkins; Nicholas B La Thangue; Robert Brown Journal: Mol Cancer Ther Date: 2003-08 Impact factor: 6.261
Authors: Jaroslav Tumas; Kotryna Kvederaviciute; Marius Petrulionis; Benediktas Kurlinkus; Arnas Rimkus; Greta Sakalauskaite; Jonas Cicenas; Audrius Sileikis Journal: Med Oncol Date: 2016-11-02 Impact factor: 3.064
Authors: Kristen K Ciombor; Yang Feng; Al Bowen Benson; Yingjun Su; Linda Horton; Sarah P Short; John Sae Wook Kauh; Charles Staley; Mary Mulcahy; Mark Powell; Katayoun I Amiri; Ann Richmond; Jordan Berlin Journal: Invest New Drugs Date: 2014-06-04 Impact factor: 3.850
Authors: M Nikbakht Dastjerdi; M R Salahshoor; M Mardani; M Rabbani; B Hashemibeni; M Gharagozloo; M Kazemi; N Esmaeil; Sh Roshankhah; R Golmohammadi; M Mobarakian Journal: Res Pharm Sci Date: 2013-04